Efficacy and safety of mometasone furoate 0.1% once daily versus fluticasone propionate 0.005% twice daily in the management of psoriasis

Advances in Therapy

Volumn 15, Issue 2, 1998, Pages 92-97

  De Villez, Richard L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Fluticasone propionate; Mometasone furoate; Psoriasis

Indexed keywords

FLUTICASONE PROPIONATE; MOMETASONE FUROATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; PATIENT SATISFACTION; PSORIASIS; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SKIN ATROPHY; TELANGIECTASIA; TOPICAL DRUG ADMINISTRATION;

EID: 0031833650     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis. 1988;42:480-485.
2. Roberts DT. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17, 21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis. 1996;57(suppl 2):27-31.